Riboflavin: Inhibitory effects on receptors, G-proteins, and adenylate cyclase

Drug Development Research

Volumn 42, Issue 2, 1997, Pages 98-108

  Daly, John W ^a   Shi, Dan ^a   Padgett, William L ^a   Ji, Xiao Duo ^a   Jacobson, Kenneth A ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

A1 adenosine receptors; Adenosine analogs; Adenylate cyclae; Forskolin; G protein; P site; Xanthine

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE RECEPTOR; ADENYLATE CYCLASE; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; RIBOFLAVIN;

ADIPOCYTE; ADIPOCYTE MEMBRANE; ANIMAL CELL; ARTICLE; BRAIN CORTEX; CELL STRAIN; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; HAMSTER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT;

EID: 0031447789     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199710)42:2<98::AID-DDR6>3.0.CO;2-K     Document Type: Article

References (20)

1. Betz AL, Ren XD, Ennis SR, Hultquist DE (1994): Riboflavin reduces edema in focal cerebral ischemia. Acta Neurochir 60:314-317.
2. 3H]phenylxanthine. Proc Natl Acad Sci USA 77:5547-5551.
3. 1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol 335:59-63.
4. Cooperman JM, Lopez, R (1991): Riboflavin. In Machlin LJ (ed): Handbook of Vitamins. New York: Marcel Dekker, pp 283-310.
5. Désaubry L, Shoshani I, Johnson RA (1996): Inhibition of adenylate cyclase by a family of newly synthesized adenine nucleoside 3′-polyphosphates. J Biol Chem 271:14028-14034.
6. Galagan ME, Mordvintcev PI, Vanin AF (1991): Effect of riboflavin on hypotensive activity of dinitrosyl iron complex with thiosulphate. Eur J Pharmacol 203:325-326.
7. Gierschik P, Moghtader R, Straub C, Dieterich K, Jakobs KH (1991): Signal amplification in HL-60 granulocytes. Evidence that the chemotactic peptide receptor catalytically activates guanine-nucleotide-binding regulatory proteins in native plasma membranes. Eur J Biochem 197:725-737.
8. Hultquist DE, Xu F, Quandt KS, Shlafer M, Mack CP, Till GO, Seekamp A, Betz AL, Ennis SR (1993): Evidence that NADPH-dependent methemoglobin reductase and administered riboflavin protect tissues from oxidative injury. Am J Hematol 42:13-18.
9. Iadecola C (1997): Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurol Sci 20:32-139.
10. Johnson RA, Yeung S-MH, Stubner D, Bushfield M, Shoshani I (1989): Cation and structural requirements for P-site mediated inhibition of adenylate cyclase. Mol Pharmacol 35:681-688.
11. Kotegawa M, Sugiyama M, Haramaki N (1994): Protective effects of riboflavin and its derivatives against ischemic reperfused damage of the heart. Biochem Mol Biol Int 34:685-691.
12. Londos C, Wolff J (1977): Two distinct adenosine-sensitive sites on adenylate cyclase. Proc Natl Acad Sci USA 74:5482-5486.
13. 35S]thio)triphosphate binding. Mol Pharmacol 44:115-123.
14. Nimit Y, Law J, Daly JW (1982): Binding of 2′,5′-dideoxyadenosine to brain membranes. Comparison to P-site inhibition of adenylate cyclase. Biochem Pharmacol 31:3279-3287.
15. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB (1992): Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 13:439-145.
16. Seamon KB, Daly JW (1982): Calmodulin stimulation of adenylate cyclase in rat brain membranes does not require GTP. Life Sci 30:1457-1464.
17. Siddiqi SM, Ji X-d, Melman N, Olah ME, Jain R, Evans P, Glashofer M, Padgett WL, Cohen LA, Daly JW, Stiles GL, Jacobson KA (1996): A survey of nonxanthine derivatives as adenosine receptor ligands. Nucleosides Nucleotides 15:693-717.
18. Tang W-J, Stanzel M, Gilman AG (1995): Truncation and alanine-scanning mutants of type 1 adenylate cyclase. Biochemistry 34:14563-14572.
19. Ukena D, Daly JW, Kirk KL, Jacobson KA (1986): Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: Potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells. Life Sci 38:797-807.
20. Von Lubitz DKJE, Lin R-C, Paul IA, Beenhakker M, Boyd M, Bischofberger N, Jacobson KA (1996): Postischemic administration of adenosine amine congener (ADAC): Analysis of recovery in gerbils. Eur J Pharmacol 316:171-179.